Author

Chuqi Wang

National University of SingaporeORCID 0009-0004-8973-5595Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Assay:metabolomics· 1 Assay:proteomics· 1

Frequent Co-Authors

Ahmed M. MamdouhiD· 2 shared Edward AyoubiD· 2 shared Fang Qi Lim· 2 shared Jordan Yong Ming TaniD· 2 shared Karanpreet Singh BhatiaiD· 2 shared Michael AndreeffiD· 2 shared Shruti BhattiD· 2 shared Xiao Xian LiniD· 2 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Ahmed M. MamdouhORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Macrophage-secreted Pyrimidine Metabolites Confer Chemotherapy Resistance in Acute Myeloid Leukemia (AML)

Chuqi Wang, Yuhan Wang, Camillo Benetti, Xiao Xian Lin, Enes Dasdemir, Petra Hyroššová, Jordan Yong Ming Tan, Edward Ayoub, Karanpreet Singh Bhatia, Fang Qi Lim, Yun Li, Zihui Zhao, Ahmed M. Mamdouh, Shir Ying Lee, Jakub Rohlena, , Shruti Bhatt

This study identifies that macrophage-secreted pyrimidine metabolites confer chemotherapy resistance in AML by inhibiting drug activation, and shows that targeting macrophage metabolism can restore drug sensitivity.

bioRxiv · Nov 1, 2025 · PreprintCancer Biology

BIRC5 dependency defines a targetable vulnerability in TP53 mutant acute myeloid leukemia

Ahmed M. Mamdouh, Fang Qi Lim, Yang Mi, Elyse A. Olesinski, Shaista Shabbir Jasdanwala, Xiao Xian Lin, Edward Ayoub, Jordan Yong Ming Tan, Karanpreet Singh Bhatia, Yichen Wang, Shradha Garnaik, Kunal Tomar, Valeriia Sapozhnikova, Cheryl Gek Teng Chan, Chuqi Wang, , Shruti Bhatt

This study identifies BIRC5 as a targetable vulnerability in TP53 mutant AML, showing that survivin/IAP inhibitors can overcome therapy resistance.

bioRxiv · May 17, 2025 · PreprintCancer Biology